Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the diarylthioether and phenol chemical classes. It was identified as an inhibitor of homoserine dehydrogenase, an enzyme involved in the biosynthesis of essential amino acids (methionine, threonine, isoleucine) in fungi such as Saccharomyces cerevisiae. The compound acts by binding to the amino acid binding region of the enzyme's active site, with its phenolic hydroxyl group forming specific interactions with key residues. This mechanism disrupts fungal amino acid biosynthesis and has been explored for antifungal activity in experimental settings. It is not approved for clinical use and remains an experimental research tool[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(4-hydroxy-3-isopropylphenylthio)-2-isopropylphenol.